FUSION ANTIBODIES PLC – Notice Of Acceptance Of Patent In Australia
RNS Number : 4758P Fusion Antibodies PLC 06 August 2026 6 August 2026 Fusion Antibodies plc (“Fusion” or the
RNS Number : 4758P Fusion Antibodies PLC 06 August 2026 6 August 2026 Fusion Antibodies plc (“Fusion” or the
A Private Investor is a recipient of the Information who meets all of the conditions set out below, the recipient:
RNS Number : 5357Y Fusion Antibodies PLC 30 March 2026 The information contained within this announcement is deemed by
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the appointment of Dr Richard Jones as Chief Executive Officer, replacing Dr Paul Kerr who stands down from the Board with immediate effect in order to pursue other opportunities. Paul will become a consultant to the Company so that he can continue to support the Company going forward.
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30 September 2020 (“H1 FY2021”).
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, is pleased to announce its final results for the year ended 31 March 2020.
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on the Company’s trading and operations over the past two months.
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on current trading.
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30 September 2019 (H1 FY2020).
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides a business and unaudited trading update for the six months ended 30 September 2019 (“H1 FY2020”), confirming continued revenue growth and the commercial roll out of new services.